Bli medlem
Bli medlem

Du är här


ViroGates A/S: Västra Hamnen: ViroGates - Detects COVID-19 relevance

Västra Hamnen Corporate Finance has published a research update on
ViroGates following its Quarterly Report for Q1 2020. The numbers
were largely in line with expectations. The bigger news is an early
indication that suPAR can be helpful in triaging COVID-19 patients,
writes Västra Hamnen.

· suPAR determines severity of COVID-19 in preliminary study
· Steady increase in hospitals evaluating suPARnostic® for clinical

· We keep our valuation interval unchanged
ViroGates published its quarterly report for Q1 2020 last week. The
figures showed somewhat lower revenues, but even lower costs compared
with our expectations, yielding a net profit slightly better than our
estimates. The report was however overshadowed by the news last
Thursday that ViroGates' suPAR test has shown to be relevant in
triaging COVID-19 patients. Clinical results show that suPAR has
significant predictive power in identifying which patients are likely
to develop severe respiratory failure (SRF). This is highly
interesting with respect to future sales of ViroGates' products.

The full report is available here

The research report is prepared as part of Market Focus, Västra Hamnen
Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB.
Twitter: @vhcorp_se (


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.